# A Study of QL1706H in Patients With Advanced Solid Tumors

> **NCT06047431** · PHASE1 · UNKNOWN · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 150 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** QL1706H

## Key facts

- **NCT ID:** NCT06047431
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-10
- **Primary completion:** 2024-12
- **Final completion:** 2025-12
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2023-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06047431

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06047431, "A Study of QL1706H in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06047431. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*